James Craven, MD
Vascular Surgery · Baton Rouge, LANPI 1518962653
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,920 of the $64,537 with a category attached, or 77.4%. Johnson & Johnson accounts for 83.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $29,289 and has fallen 99.0% since, to $305 in 2024. Among vascular surgery clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 126 payments — averaging $512.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$54K
- Silk Road Medical, Inc.$7K
- W. L. Gore & Associates, Inc.$788
- Cvrx, Inc.$573
- Inari Medical, Inc.$568
- Cardiovascular Systems Inc.$384
- plus $1K from 15 others
Across 15 payments — averaging $422.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endologix LLC$6K
What the payments were for
- Consulting fees$6,30010%
- Speaking & faculty fees$49,92077%
- Travel & lodging$3,4725%
- Food & beverage$4,8458%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 59 | $53,873 |
| Silk Road Medical, Inc. | 16 | $7,304 |
| W. L. Gore & Associates, Inc. | 6 | $788 |
| Cvrx, Inc. | 3 | $573 |
| Inari Medical, Inc. | 6 | $568 |
| Cardiovascular Systems Inc. | 4 | $384 |
| Smith+Nephew | 10 | $219 |
| Medtronic(2 entities) | 4 | $189 |
| Bard Peripheral Vascular, Inc. | 2 | $156 |
| Penumbra, Inc. | 1 | $151 |
| Intuitive Surgical | 1 | $80 |
| Pfizer | 3 | $48 |
| Philips North America LLC | 2 | $46 |
| Boehringer Ingelheim | 2 | $28 |
| Aroa Biosurgery Incorporated | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $21 |
| Apria Healthcare LLC | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Surmodics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$52,758
- ENROUTE Transcarotid Neuroprotection System$7,007
- ENROUTE Transcarotid Stent System$7,007
- ENHANCE Transcarotid Peripheral Access Kit$7,007
- ENROUTE 0.014 Guidewire$7,007
- FLOWTRIEVER CATHETER, S$650
- Barostim Neo System$472
- GORE TAG Thoracic Endoprosthesis$335
- GORE TAG Conformable Thoracic Endoprosthesis$321
- Diamondback Peripheral$262
- CT THROMBECTOMY SYSTEM KIT$159
- Ruby$151
- LUTONIX$135
- Heli-FX EndoAnchor System$129
How this compares
$64,537 in reported general payments places this provider in the 95th percentile of 65 vascular surgery providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 13 | $7,299 |
| ClopidogrelClopidogrel Bisulfate | 70 | $447 |
| Atorvastatin Calcium | 13 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $53,873 | $7,29913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 65 vascular surgery providers in Louisiana.
Other vascular surgery in Baton Rouge
- Michael Conners IiiBaton Rouge$70K
- Marvin WeaverBaton Rouge$58K
- London GuidryBaton Rouge$25K
- Paul DavisBaton Rouge$18K
- Gulrez MahmoodBaton Rouge$9K
- Matthew AbateBaton Rouge$9K
- Wajeeh IrfanBaton Rouge$7K
- Taylor GwinBaton Rouge$7K
- Madeline DillsBaton Rouge$5K
- James McNeilBaton Rouge$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.